Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages

Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among […]

Leave a Reply

Your email address will not be published.

Previous post Aris Water Solutions, Inc. (NYSE:ARIS) Receives $20.83 Consensus Price Target from Analysts
Next post Ski Wednesday: Blue Hills Ski Area Sign Post